Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Ignacio Durán et al.|The Lancet|2017Cited by 1.4k
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100Markus Moehler, Yung‐Jue Bang, Antonio Cubillo Gracián et al.|Journal of Clinical Oncology|2020Cited by 222
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Paul J. Kostenuik, Henry G. Bone et al.|European Journal of Cancer|2015Cited by 150
Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)Jun Masuda, Toshimi Takano|Journal for ImmunoTherapy of Cancer|2023Cited by 65
P3-16-07: Denosumab in Patients with Breast Cancer and Bone Metastases Previously Treated with Zoledronic Acid or Denosumab: Results from the 2-Year Open-Label Extension Treatment Phase of a Pivotal Phase 3 Study.A. Stopeck, Ada Braun, Allan Lipton et al.|Cancer Research|2011Cited by 15